The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia

Stem Cells

Volumn 18, Issue 5, 2000, Pages 360-365

  Case, Beth C ^a   Hauck, Marlene L ^a   Yeager, Russell L ^b   Simkins, Anita H ^b   De Serres, Mark ^b   Schmith, Virginia D ^b   Dillberger, John E ^b   Page, Rodney L ^a,c  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Canine; GW395058; Mimetic peptide; Pharmacodynamics; Pharmacokinetics; Thrombocytopenia; Thrombopoietin

Indexed keywords

CARBOPLATIN; ENROFLOXACIN; GW 395058; PEPTIDE DERIVATIVE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; FEMALE; MALE; NEUTROPENIA; NONHUMAN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033830462     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-5-360     Document Type: Article

References (24)

1. Results of NCI-sponsored phase I trials with carboplatin
2. A multicentric study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
3. Noninfectious adverse reactions to blood transfusion
4. Effects of interleukin-1α on carbolatin-induced thrombocytopenia in patients with recurrent ovarian cancer
5. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies
6. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer
7. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study
8. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase Ib study
9. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies
10. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy
11. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
12. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
13. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy and lung cancer
14. Recombinant human thrombopoietin: Clinical experience and in vivo biology
15. Clinical studies with megakaryocyte growth and development factor (Mpl-ligand)
16. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine
17. Pegylated thrombopoietin (TPO)-mimetic peptides bind human TPO receptor causing proliferation and maturation of megakaryocytes
18. PEGylated thrombopoietin-mimetic peptides elevate blood platelets and ablate the chemotherapy-induced platelet nadir in mice
19. Immunogenicity studies of the thrombopoietin mimetic peptide GW395058 in BALB/c mice, New Zealand White Rabbits, and Cynomolgus Monkey
20. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand White rabbits: Evaluation of the potential for thrombopoietin neutralizing antibody production in man
21. Pharmacokinetic and phase I evaluation of carboplatin in dogs
22. Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration